Chemical: Drug
metoprolol

last updated 02/07/2014

1. DPWG Guideline for metoprolol and CYP2D6

Summary

Select another drug or reduce dose of metoprolol for CYP2D6 poor and intermediate metabolizer patients. Use a dose titration of metoprolol for CYP2D6 ultra metabolizers or select an alternative drug.

Annotation

The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for metoprolol based on CYP2D6 genotype [Article:21412232]. They recommend either selecting another drug or dose reduction for poor and intermediate metabolizer patients, with dose titration for ultra metabolizers.

Phenotype (Genotype) Therapeutic Dose Recommendation Level of Evidence Clinical Relevance
PM (2 inactive alleles) Heart failure: select alternative drug (e.g., bisoprolol, carvedilol) or reduce dose by 75%. Other indications: be alert to ADEs (e.g., bradycardia, cold extremities) or select alternative drug (e.g., atenolol, bisoprolol). Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints. Clinical effect (S): long-standing discomfort (48-168 hr) without permanent injury e.g. failure of therapy with tricyclic antidepressants, atypical antipsychotic drugs; extrapyramidal side effects; parkinsonism; ADE resulting from increased bioavailability of tricyclic antidepressants, metoprolol, propafenone (central effects e.g. dizziness); INR 4.5-6.0; neutropenia 1.0-1.5x10^9/l; leucopenia 2.0-3.0x10^9/l; thrombocytopenia 50-75x10^9/l.
IM (2 decreased activity alleles, or 1 active and 1 inactive allele, or 1 decreased activity and 1 inactive allele) Heart failure: select alternative drug (e.g., bisoprolol, carvedilol) or reduce dose by 50%. Other indications: be alert to ADEs (e.g., bradycardia, cold extremities) or select alternative drug (e.g., atenolol, bisoprolol). Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints. Clinical effect (S): short-lived discomfort (< 48 hr) without permanent injury: e.g. reduced decrease in resting heart rate; reduction in exercise tachycardia; decreased pain relief from oxycodone; ADE resulting from increased bioavailability of atomoxetine (decreased appetite, insomnia, sleep disturbance etc); neutropenia > 1.5x10^9/l; leucopenia > 3.0x10^9/l; thrombocytopenia > 75x10^9/l; moderate diarrhea not affecting daily activities; reduced glucose increase following oral glucose tolerance test.
UM (gene duplication in absence of inactive or decreased activity alleles) Heart failure: select alternative drug (e.g., bisoprolol, carvedilol) or titrate dose to a maximum of 250% of the normal dose in response to efficacy and ADE. Other indications: select alternative drug (e.g., atenolol, bisoprolol) or titrate dose to a maximum of 250% of the normal dose in response to efficacy and ADE. Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints. Clinical effect (S): long-standing discomfort (> 168 hr), permanent symptom or invalidating injury e.g. failure of prophylaxis of atrial fibrillation; venous thromboembolism; decreased effect of clopidogrel on inhibition of platelet aggregation; ADE resulting from increased bioavailability of phenytoin; INR > 6.0; neutropenia 0.5-1.0x10^9/l; leucopenia 1.0-2.0x10^9/l; thrombocytopenia 25-50x10^9/l; severe diarrhea.
Allele Type Alleles
active *1, *2, *33, *35
decreased activity *9, *10, *17, *29, *36, *41
inactive *3-*8, *11-*16, *19-*21, *38, *40, *42


Annotated Labels

  1. FDA Label for metoprolol and CYP2D6
  2. HCSC Label for metoprolol and CYP2D6

last updated 10/25/2013

1. FDA Label for metoprolol and CYP2D6

Informative PGx

Summary

Metoprolol is metabolized by the cytochrome P450 enzymes in the liver with a major contribution of CYP2D6. Poor metabolizers and extensive metabolizers who concomitantly use CYP2D6 inhibiting drugs will have increased (several-fold) metoprolol blood levels, decreasing metoprolol's cardioselectivity.

Annotation

Metoprolol is a selective beta1-adrenoreceptor blocking agent used for the treatment of hypertension, angina pectoris, and acute myocardial infarction. Metoprolol is metabolized by the cytochrome P450 enzymes in the liver with a major contribution of CYP2D6.

Excerpts from the Metoprolol drug label:

Metoprolol is metabolized predominantly by CYP2D6, an enzyme that is absent in about 8% of Caucasians (poor metabolizers) and about 2% of most other populations. CYP2D6 can be inhibited by a number of drugs. Poor metabolizers and extensive metabolizers who concomitantly use CYP2D6 inhibiting drugs will have increased (several-fold) metoprolol blood levels, decreasing metoprolol's cardioselectivity.

For the complete drug label text with sections containing pharmacogenetic information highlighted, see the Metoprolol drug label.

*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.

Full label available at DailyMed

Genes and/or phenotypes found in this label

  • Heart Failure
    • Indications & usage section, Contraindications section, Warnings section, Adverse reactions section
    • source: PHONT
  • Hypertension
    • Indications & usage section, Contraindications section, Warnings section, Adverse reactions section
    • source: PHONT
  • CYP2D6
    • metabolism/PK, Drug interactions section, Pharmacokinetics section
    • source: U.S. Food and Drug Administration

last updated 06/08/2015

2. HCSC Label for metoprolol and CYP2D6

Actionable PGx

Summary

The product monograph for metoprolol notes that CYP2D6 poor metabolizers exhibit higher plasma concentrations of the drug as compared to extensive metabolizers, however these differences in plasma concentrations seem to have little to no effect on safety or tolerability.

Annotation

Metoprolol is a beta-adrenergic receptor-blocking agent. Excerpts from the metoprolol product monograph:

The oxidative metabolism of metoprolol is under genetic control with a major contribution of the polymorphic cytochrome P450 isoform 2D6 (CYP2D6). There are marked ethnic differences in the prevalence of the poor metabolizers (PM) phenotype. Approximately 7% of Caucasians and less than 1% Orientals are PMs.

CYP2D6 poor metabolizers exhibit several-fold higher plasma concentrations of metoprolol than extensive metabolizers with normal CYP2D6 activity. However, the cytochrome P450 2D6 dependent metabolism of metoprolol seems to have little or no effect on safety or tolerability of the drug. None of the metabolites of metoprolol contribute significantly to its beta-blocking effect.

For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the metoprolol product monograph.

*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.


PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the page.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page.

Links in the "Gene" column lead to PharmGKB Gene Pages.

List of all variant annotations for metoprolol

Gene ? Variant?
(147)
Alternate Names ? Chemicals ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available No VIP available VA CYP2C19 *2 N/A N/A N/A
No VIP available No VIP available VA CYP2C19 *3 N/A N/A N/A
VIP CA VA CYP2D6 *1 N/A N/A N/A
No VIP available No VIP available VA CYP2D6 *1xN N/A N/A N/A
VIP No VIP available VA CYP2D6 *2 N/A N/A N/A
No VIP available No VIP available VA CYP2D6 *2xN N/A N/A N/A
VIP CA VA CYP2D6 *3 N/A N/A N/A
VIP CA VA CYP2D6 *4 N/A N/A N/A
No VIP available CA VA CYP2D6 *5 N/A N/A N/A
VIP CA VA CYP2D6 *6 N/A N/A N/A
VIP CA VA CYP2D6 *9 N/A N/A N/A
VIP CA VA CYP2D6 *10 N/A N/A N/A
VIP CA VA CYP2D6 *17 N/A N/A N/A
No VIP available CA VA CYP2D6 *20 N/A N/A N/A
VIP CA VA CYP2D6 *29 N/A N/A N/A
No VIP available CA VA CYP2D6 *31 N/A N/A N/A
No VIP available CA VA CYP2D6 *35 N/A N/A N/A
VIP CA VA CYP2D6 *41 N/A N/A N/A
No VIP available No VIP available VA CYP2D6 *45 N/A N/A N/A
No VIP available No VIP available VA CYP2D6 *46 N/A N/A N/A
No VIP available No Clinical Annotations available VA
CYP2D6 poor metabolizer N/A N/A N/A
No VIP available No Clinical Annotations available VA
CYP2D6 extensive metabolizers N/A N/A N/A
No VIP available CA VA
rs1024323 NC_000004.11:g.3006043C>T, NC_000004.12:g.3004316C>T, NG_029102.1:g.45701C>T, NM_001004056.1:c.329C>T, NM_001004057.1:c.425C>T, NM_005307.2:c.329C>T, NM_182982.2:c.425C>T, NP_001004056.1:p.Ala110Val, NP_001004057.1:p.Ala142Val, NP_005298.2:p.Ala110Val, NP_892027.2:p.Ala142Val, XM_005247957.1:c.425C>T, XM_005247958.1:c.329C>T, XM_005247959.1:c.425C>T, XM_005247960.1:c.425C>T, XM_005247962.1:c.-209C>T, XM_005247962.2:c.-209C>T, XM_005247963.1:c.425C>T, XM_006713880.2:c.-237C>T, XM_011513447.1:c.425C>T, XM_011513448.1:c.425C>T, XM_011513449.1:c.329C>T, XM_011513450.1:c.425C>T, XM_011513451.1:c.425C>T, XM_011513452.1:c.425C>T, XM_011513453.1:c.425C>T, XM_011513454.1:c.425C>T, XM_011513455.1:c.425C>T, XM_011513456.1:c.425C>T, XM_011513457.1:c.425C>T, XP_005248014.1:p.Ala142Val, XP_005248015.1:p.Ala110Val, XP_005248016.1:p.Ala142Val, XP_005248017.1:p.Ala142Val, XP_005248020.1:p.Ala142Val, XP_011511749.1:p.Ala142Val, XP_011511750.1:p.Ala142Val, XP_011511751.1:p.Ala110Val, XP_011511752.1:p.Ala142Val, XP_011511753.1:p.Ala142Val, XP_011511754.1:p.Ala142Val, XP_011511755.1:p.Ala142Val, XP_011511756.1:p.Ala142Val, XP_011511757.1:p.Ala142Val, XP_011511758.1:p.Ala142Val, XP_011511759.1:p.Ala142Val, XR_924941.1:n.991C>T, XR_924943.1:n.991C>T, rs386511346, rs52795674, rs61636656
C > T
SNP
A110V
No VIP available No Clinical Annotations available VA
rs1042713 NC_000005.10:g.148826877G=, NC_000005.10:g.148826877G>A, NC_000005.9:g.148206440G=, NC_000005.9:g.148206440G>A, NG_016421.1:g.5285A=, NG_016421.1:g.5285A>G, NM_000024.5:c.46A=, NM_000024.5:c.46A>G, NP_000015.1:p.Arg16=, NP_000015.1:p.Arg16Gly, XM_005268382.1:c.46G=, XM_005268382.1:c.46G>A, XM_005268383.1:c.46G=, XM_005268383.1:c.46G>A, XP_005268439.1:p.Gly16=, XP_005268439.1:p.Gly16Arg, XP_005268440.1:p.Gly16=, XP_005268440.1:p.Gly16Arg, rs17287432, rs17334179, rs17334242, rs17721693, rs17839749, rs17846639, rs17859732, rs3182174, rs3729940, rs52812686, rs56964295
G > A
SNP
R16G
No VIP available CA VA
rs1042714 NC_000005.10:g.148826910G=, NC_000005.10:g.148826910G>C, NC_000005.9:g.148206473G=, NC_000005.9:g.148206473G>C, NG_016421.1:g.5318C=, NG_016421.1:g.5318C>G, NM_000024.5:c.79C=, NM_000024.5:c.79C>G, NP_000015.1:p.Gln27=, NP_000015.1:p.Gln27Glu, XM_005268382.1:c.79G=, XM_005268382.1:c.79G>C, XM_005268383.1:c.79G=, XM_005268383.1:c.79G>C, XP_005268439.1:p.Glu27=, XP_005268439.1:p.Glu27Gln, XP_005268440.1:p.Glu27=, XP_005268440.1:p.Glu27Gln, rs17287411, rs17287474, rs17334200, rs17640526, rs17845338, rs17858183, rs17859733, rs3182175, rs3729941, rs52793394, rs60374884
G > C
G > T
SNP
Q27E
VIP No Clinical Annotations available No Variant Annotations available
rs1065852 NC_000022.10:g.42526694G=, NC_000022.10:g.42526694G>A, NC_000022.11:g.42130692G=, NC_000022.11:g.42130692G>A, NG_008376.3:g.4300C=, NG_008376.3:g.4300C>T, NM_000106.5:c.100C=, NM_000106.5:c.100C>T, NM_001025161.2:c.100C=, NM_001025161.2:c.100C>T, NP_000097.3:p.Pro34=, NP_000097.3:p.Pro34Ser, NP_001020332.2:p.Pro34=, NP_001020332.2:p.Pro34Ser, NT_187682.1:g.53033G=, NT_187682.1:g.53033G>A, NW_004504305.1:g.53019A=, NW_004504305.1:g.53019A>G, NW_009646208.1:g.16258A=, NW_009646208.1:g.16258A>G, XM_005278353.1:c.100T=, XM_005278353.1:c.100T>C, XM_005278354.1:c.-1454C>T, XM_005278354.1:c.-1454T>C, XM_005278354.3:c.-1454C>T, XM_005278354.3:c.-1454T>C, XM_011529966.1:c.100C=, XM_011529966.1:c.100C>T, XM_011529967.1:c.100C=, XM_011529967.1:c.100C>T, XM_011529968.1:c.100C=, XM_011529968.1:c.100C>T, XM_011529969.1:c.37+605C>T, XM_011529969.1:c.37+605T>C, XM_011529970.1:c.100C=, XM_011529970.1:c.100C>T, XM_011529971.1:c.37+605C>T, XM_011529971.1:c.37+605T>C, XM_011529972.1:c.100C=, XM_011529972.1:c.100C>T, XM_011547541.1:c.-1454C>T, XM_011547541.1:c.-1454T>C, XM_011547750.1:c.37+605C>T, XM_011547750.1:c.37+605T>C, XM_011547751.1:c.-1114C>T, XM_011547751.1:c.-1114T>C, XM_011547756.1:c.42+469A>G, XM_011547756.1:c.42+469G>A, XM_011548819.1:c.-1454C>T, XM_011548819.1:c.-1454T>C, XP_005278410.1:p.Ser34=, XP_005278410.1:p.Ser34Pro, XP_011528268.1:p.Pro34=, XP_011528268.1:p.Pro34Ser, XP_011528269.1:p.Pro34=, XP_011528269.1:p.Pro34Ser, XP_011528270.1:p.Pro34=, XP_011528270.1:p.Pro34Ser, XP_011528272.1:p.Pro34=, XP_011528272.1:p.Pro34Ser, XP_011528274.1:p.Pro34=, XP_011528274.1:p.Pro34Ser, XR_430455.2:n.328+4A>G, XR_430455.2:n.328+4G>A, XR_952536.1:n.-1751A>G, XR_952536.1:n.-1751G>A, XR_952537.1:n.-1751A>G, XR_952537.1:n.-1751G>A, XR_952538.1:n.-1751A>G, XR_952538.1:n.-1751G>A, XR_952539.1:n.-1462A>G, XR_952539.1:n.-1462G>A, XR_952745.1:n.1257C=, XR_952745.1:n.1257C>T, rs117813846, rs58862176
G > A
SNP
P34S
No VIP available CA VA
rs11313667 NC_000003.11:g.194082162delC, NC_000003.12:g.194361433delC, NM_001135057.2:c.16-387del, NM_001135057.2:c.16-387delG, NM_130830.4:c.-3-387del, NM_130830.4:c.-3-387delG, rs151082125, rs35134266, rs375356868, rs376304527, rs61050302, rs79846527
C > -
indel
No VIP available No Clinical Annotations available VA
rs1367094 NC_000008.10:g.40402374C>T, NC_000008.11:g.40544855C>T, NM_001135731.1:c.447-12617G>A, NM_024645.2:c.675-12617G>A, XM_005273643.1:c.578-12617G>A, XM_005273644.1:c.537-12617G>A, XM_011544643.1:c.705-12617G>A, XM_011544644.1:c.608-12617G>A, XM_011544645.1:c.477-12617G>A
C > T
SNP
VIP No Clinical Annotations available No Variant Annotations available
rs16947 NC_000022.10:g.42523943A=, NC_000022.10:g.42523943A>G, NC_000022.11:g.42127941G=, NC_000022.11:g.42127941G>A, NG_008376.3:g.7051C=, NG_008376.3:g.7051C>T, NM_000106.5:c.886C=, NM_000106.5:c.886C>T, NM_001025161.2:c.733C=, NM_001025161.2:c.733C>T, NP_000097.3:p.Arg296=, NP_000097.3:p.Arg296Cys, NP_001020332.2:p.Arg245=, NP_001020332.2:p.Arg245Cys, NT_187682.1:g.50282A=, NT_187682.1:g.50282A>G, NW_004504305.1:g.50268G=, NW_004504305.1:g.50268G>A, NW_009646208.1:g.13507G=, NW_009646208.1:g.13507G>A, XM_005278353.1:c.742C=, XM_005278353.1:c.742C>T, XM_005278354.1:c.586C=, XM_005278354.1:c.586C>T, XM_005278354.3:c.586C=, XM_005278354.3:c.586C>T, XM_011529966.1:c.886C=, XM_011529966.1:c.886C>T, XM_011529967.1:c.886C=, XM_011529967.1:c.886C>T, XM_011529968.1:c.886C=, XM_011529968.1:c.886C>T, XM_011529969.1:c.742C=, XM_011529969.1:c.742C>T, XM_011529970.1:c.733C=, XM_011529970.1:c.733C>T, XM_011529971.1:c.742C=, XM_011529971.1:c.742C>T, XM_011529972.1:c.843+233C>T, XM_011529972.1:c.843+233T>C, XM_011547541.1:c.586C=, XM_011547541.1:c.586C>T, XM_011547750.1:c.742T=, XM_011547750.1:c.742T>C, XM_011547751.1:c.670T=, XM_011547751.1:c.670T>C, XM_011547756.1:c.-2094A>G, XM_011547756.1:c.-2094G>A, XM_011548819.1:c.586C=, XM_011548819.1:c.586C>T, XP_005278410.1:p.Arg248=, XP_005278410.1:p.Arg248Cys, XP_005278411.1:p.Arg196=, XP_005278411.1:p.Arg196Cys, XP_011528268.1:p.Arg296=, XP_011528268.1:p.Arg296Cys, XP_011528269.1:p.Arg296=, XP_011528269.1:p.Arg296Cys, XP_011528270.1:p.Arg296=, XP_011528270.1:p.Arg296Cys, XP_011528271.1:p.Arg248=, XP_011528271.1:p.Arg248Cys, XP_011528272.1:p.Arg245=, XP_011528272.1:p.Arg245Cys, XP_011528273.1:p.Arg248=, XP_011528273.1:p.Arg248Cys, XP_011545843.1:p.Arg196=, XP_011545843.1:p.Arg196Cys, XP_011546052.1:p.Cys248=, XP_011546052.1:p.Cys248Arg, XP_011546053.1:p.Cys224=, XP_011546053.1:p.Cys224Arg, XP_011547121.1:p.Arg196=, XP_011547121.1:p.Arg196Cys, XR_430455.2:n.-1930A>G, XR_430455.2:n.-1930G>A, XR_952745.1:n.2000+233C>T, XR_952745.1:n.2000+233T>C, rs117039205, rs57836231
A > G
SNP
R296C
VIP No Clinical Annotations available No Variant Annotations available
rs1799752 NC_000017.10:g.61565890_61565891insATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC, NC_000017.10:g.61565890_61565891insG, NC_000017.11:g.63488529_63488530insATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC, NC_000017.11:g.63488529_63488530insG, NG_011648.1:g.16457_16458insATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC, NG_011648.1:g.16457_16458insG, NM_000789.3:c.2306-119_2306-118insATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC, NM_000789.3:c.2306-119_2306-118insG, NM_001178057.1:c.584-119_584-118insATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC, NM_001178057.1:c.584-119_584-118insG, NM_152830.2:c.584-119_584-118insATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC, NM_152830.2:c.584-119_584-118insG, XM_005257110.1:c.1757-119_1757-118insATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC, XM_005257110.1:c.1757-119_1757-118insG, XM_006721737.2:c.644-119_644-118insATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC, XM_006721737.2:c.644-119_644-118insG
- > ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC
- > G
indel
No VIP available No Clinical Annotations available VA
rs1800888 NC_000005.10:g.148827322C>T, NC_000005.9:g.148206885C>T, NG_016421.1:g.5730C>T, NM_000024.5:c.491C>T, NP_000015.1:p.Thr164Ile, XM_005268382.1:c.491C>T, XM_005268383.1:c.491C>T, XP_005268439.1:p.Thr164Ile, XP_005268440.1:p.Thr164Ile, rs17334207, rs17707796, rs3729606
C > T
SNP
T164I
No VIP available CA VA
rs1801058 NC_000004.11:g.3039150T>C, NC_000004.12:g.3037423T>C, NG_029102.1:g.78808T>C, NM_001004056.1:c.1361T>C, NM_001004057.1:c.1457T>C, NM_005307.2:c.1361T>C, NM_182982.2:c.1457T>C, NP_001004056.1:p.Val454Ala, NP_001004057.1:p.Val486Ala, NP_005298.2:p.Val454Ala, NP_892027.2:p.Val486Ala, XM_005247957.1:c.1319T>C, XM_005247958.1:c.1361T>C, XM_005247959.1:c.1319T>C, XM_005247960.1:c.1270-3149T>C, XM_005247961.1:c.875T>C, XM_005247962.1:c.824T>C, XM_005247962.2:c.824T>C, XM_005247963.1:c.971-3149T>C, XM_006713880.2:c.824T>C, XM_011513447.1:c.1574T>C, XM_011513448.1:c.1574T>C, XM_011513449.1:c.1478T>C, XM_011513450.1:c.1574T>C, XM_011513451.1:c.1436T>C, XM_011513452.1:c.1436T>C, XM_011513453.1:c.1524+1900T>C, XM_011513454.1:c.1436T>C, XM_011513455.1:c.1387-3149T>C, XM_011513456.1:c.1088-3149T>C, XP_005248014.1:p.Val440Ala, XP_005248015.1:p.Val454Ala, XP_005248016.1:p.Val440Ala, XP_005248018.1:p.Val292Ala, XP_005248019.1:p.Val275Ala, XP_006713943.1:p.Val275Ala, XP_011511749.1:p.Val525Ala, XP_011511750.1:p.Val525Ala, XP_011511751.1:p.Val493Ala, XP_011511752.1:p.Val525Ala, XP_011511753.1:p.Val479Ala, XP_011511754.1:p.Val479Ala, XP_011511756.1:p.Val479Ala, XR_924941.1:n.2257T>C, XR_924943.1:n.1811T>C, rs52812762, rs56574318, rs56725050
T > C
SNP
V454A
rs1801252 NC_000010.10:g.115804036A>G, NC_000010.11:g.114044277A>G, NG_012187.1:g.5231A>G, NM_000684.2:c.145A>G, NP_000675.1:p.Ser49Gly, rs12720482, rs3740152
A > G
SNP
S49G
rs1801253 NC_000010.10:g.115805056G>C, NC_000010.11:g.114045297G>C, NG_012187.1:g.6251G>C, NM_000684.2:c.1165G>C, NP_000675.1:p.Gly389Arg, rs12718339, rs17091259, rs28365052, rs59130083
G > C
SNP
G389R
No VIP available CA VA
rs201279313 NC_000004.11:g.128657041_128657043delTTA, NC_000004.12:g.127735886_127735888delTTA, NM_001318467.1:c.232+5109_232+5111del, NM_001318467.1:c.232+5109_232+5111delTTA, NM_031291.3:c.232+5109_232+5111del, NM_031291.3:c.232+5109_232+5111delTTA, XM_011532297.1:c.232+5109_232+5111del, XM_011532298.1:c.232+5109_232+5111del
TTA > -
indel
VIP No Clinical Annotations available No Variant Annotations available
rs28371706 NC_000022.10:g.42525772G>A, NC_000022.11:g.42129770G>A, NG_008376.3:g.5222C>T, NM_000106.5:c.320C>T, NM_001025161.2:c.320C>T, NP_000097.3:p.Thr107Ile, NP_001020332.2:p.Thr107Ile, NT_187682.1:g.52111G>A, NW_004504305.1:g.52097G>A, NW_009646208.1:g.15336G>A, XM_005278353.1:c.320C>T, XM_005278354.1:c.-532C>T, XM_005278354.3:c.-532C>T, XM_011529966.1:c.320C>T, XM_011529967.1:c.320C>T, XM_011529968.1:c.320C>T, XM_011529969.1:c.177C>T, XM_011529970.1:c.320C>T, XM_011529971.1:c.177C>T, XM_011529972.1:c.320C>T, XM_011547541.1:c.-532C>T, XM_011547750.1:c.177C>T, XM_011547751.1:c.-192C>T, XM_011547756.1:c.-265G>A, XM_011548819.1:c.-532C>T, XP_005278410.1:p.Thr107Ile, XP_011528268.1:p.Thr107Ile, XP_011528269.1:p.Thr107Ile, XP_011528270.1:p.Thr107Ile, XP_011528271.1:p.His59=, XP_011528272.1:p.Thr107Ile, XP_011528273.1:p.His59=, XP_011528274.1:p.Thr107Ile, XP_011546052.1:p.His59=, XR_430455.2:n.-101G>A, XR_952745.1:n.1477C>T, rs587777915, rs59604033
G > A
SNP
T107I
VIP No Clinical Annotations available No Variant Annotations available
rs28371725 NC_000022.10:g.42523805C>T, NC_000022.11:g.42127803C>T, NG_008376.3:g.7189G>A, NM_000106.5:c.985+39G>A, NM_001025161.2:c.832+39G>A, NT_187682.1:g.50144C>T, NW_004504305.1:g.50130C>T, NW_009646208.1:g.13369C>T, XM_005278353.1:c.841+39G>A, XM_005278354.1:c.685+39G>A, XM_005278354.3:c.685+39G>A, XM_011529966.1:c.985+39G>A, XM_011529967.1:c.985+39G>A, XM_011529968.1:c.985+39G>A, XM_011529969.1:c.841+39G>A, XM_011529970.1:c.832+39G>A, XM_011529971.1:c.841+39G>A, XM_011529972.1:c.844-169G>A, XM_011547541.1:c.724G>A, XM_011547750.1:c.841+39G>A, XM_011547751.1:c.769+39G>A, XM_011548819.1:c.724G>A, XP_011545843.1:p.Glu242Lys, XP_011547121.1:p.Glu242Lys, XR_952745.1:n.2001-169G>A, rs57124011, rs587777916
C > T
SNP
No VIP available No Clinical Annotations available VA
rs2960306 NC_000004.11:g.2990499G>T, NC_000004.12:g.2988772G>T, NG_029102.1:g.30157G>T, NM_001004056.1:c.98G>T, NM_001004057.1:c.194G>T, NM_005307.2:c.98G>T, NM_182982.2:c.194G>T, NP_001004056.1:p.Arg33Leu, NP_001004057.1:p.Arg65Leu, NP_005298.2:p.Arg33Leu, NP_892027.2:p.Arg65Leu, XM_005247957.1:c.194G>T, XM_005247958.1:c.98G>T, XM_005247959.1:c.194G>T, XM_005247960.1:c.194G>T, XM_005247962.1:c.-372-3443G>T, XM_005247962.2:c.-372-3443G>T, XM_005247963.1:c.194G>T, XM_006713880.2:c.-400-3443G>T, XM_011513447.1:c.194G>T, XM_011513448.1:c.194G>T, XM_011513449.1:c.98G>T, XM_011513450.1:c.194G>T, XM_011513451.1:c.194G>T, XM_011513452.1:c.194G>T, XM_011513453.1:c.194G>T, XM_011513454.1:c.194G>T, XM_011513455.1:c.194G>T, XM_011513456.1:c.194G>T, XM_011513457.1:c.194G>T, XP_005248014.1:p.Arg65Leu, XP_005248015.1:p.Arg33Leu, XP_005248016.1:p.Arg65Leu, XP_005248017.1:p.Arg65Leu, XP_005248020.1:p.Arg65Leu, XP_011511749.1:p.Arg65Leu, XP_011511750.1:p.Arg65Leu, XP_011511751.1:p.Arg33Leu, XP_011511752.1:p.Arg65Leu, XP_011511753.1:p.Arg65Leu, XP_011511754.1:p.Arg65Leu, XP_011511755.1:p.Arg65Leu, XP_011511756.1:p.Arg65Leu, XP_011511757.1:p.Arg65Leu, XP_011511758.1:p.Arg65Leu, XP_011511759.1:p.Arg65Leu, XR_924941.1:n.760G>T, XR_924943.1:n.760G>T, rs57066640
G > T
SNP
R33L
VIP No Clinical Annotations available No Variant Annotations available
rs35742686 NC_000022.10:g.42524244delT, NC_000022.11:g.42128242delT, NG_008376.3:g.6750delA, NM_000106.5:c.775delA, NM_001025161.2:c.622delA, NP_000097.3:p.Arg259Glyfs, NP_001020332.2:p.Arg208Glyfs, NT_187682.1:g.50583delT, NW_004504305.1:g.50569delT, NW_009646208.1:g.13808delT, XM_005278353.1:c.631delA, XM_005278354.1:c.475delA, XM_005278354.3:c.475delA, XM_011529966.1:c.775delA, XM_011529967.1:c.775delA, XM_011529968.1:c.775delA, XM_011529969.1:c.631delA, XM_011529970.1:c.622delA, XM_011529971.1:c.631delA, XM_011529972.1:c.775delA, XM_011547541.1:c.475delA, XM_011547750.1:c.631delA, XM_011547751.1:c.559delA, XM_011547756.1:c.-1793delT, XM_011548819.1:c.475delA, XP_005278410.1:p.Arg211Glyfs, XP_005278411.1:p.Arg159Glyfs, XP_011528268.1:p.Arg259Glyfs, XP_011528269.1:p.Arg259Glyfs, XP_011528270.1:p.Arg259Glyfs, XP_011528271.1:p.Arg211Glyfs, XP_011528272.1:p.Arg208Glyfs, XP_011528273.1:p.Arg211Glyfs, XP_011528274.1:p.Arg259Glyfs, XP_011545843.1:p.Arg159Glyfs, XP_011546052.1:p.Arg211Glyfs, XP_011546053.1:p.Arg187Glyfs, XP_011547121.1:p.Arg159Glyfs, XR_430455.2:n.-1629delT, XR_952745.1:n.1932delA, rs45593132, rs60790764
T > -
T > T
indel
R259G
rs3892097 NC_000022.10:g.42524947C=, NC_000022.10:g.42524947C>T, NC_000022.11:g.42128945C=, NC_000022.11:g.42128945C>T, NG_008376.3:g.6047G=, NG_008376.3:g.6047G>A, NM_000106.5:c.506-1A>G, NM_000106.5:c.506-1G>A, NM_001025161.2:c.353-1A>G, NM_001025161.2:c.353-1G>A, NT_187682.1:g.51286C=, NT_187682.1:g.51286C>T, NW_004504305.1:g.51272T=, NW_004504305.1:g.51272T>C, NW_009646208.1:g.14511C=, NW_009646208.1:g.14511C>T, XM_005278353.1:c.363-2A>G, XM_005278353.1:c.363-2G>A, XM_005278354.1:c.207-2A>G, XM_005278354.1:c.207-2G>A, XM_005278354.3:c.207-2A>G, XM_005278354.3:c.207-2G>A, XM_011529966.1:c.506-1A>G, XM_011529966.1:c.506-1G>A, XM_011529967.1:c.506-1A>G, XM_011529967.1:c.506-1G>A, XM_011529968.1:c.506-1A>G, XM_011529968.1:c.506-1G>A, XM_011529969.1:c.363-2A>G, XM_011529969.1:c.363-2G>A, XM_011529970.1:c.353-1A>G, XM_011529970.1:c.353-1G>A, XM_011529971.1:c.363-2A>G, XM_011529971.1:c.363-2G>A, XM_011529972.1:c.506-1A>G, XM_011529972.1:c.506-1G>A, XM_011547541.1:c.207-2A>G, XM_011547541.1:c.207-2G>A, XM_011547750.1:c.363-2A>G, XM_011547750.1:c.363-2G>A, XM_011547751.1:c.290-1A>G, XM_011547751.1:c.290-1G>A, XM_011547756.1:c.-1090C>T, XM_011547756.1:c.-1090T>C, XM_011548819.1:c.207-2A>G, XM_011548819.1:c.207-2G>A, XR_430455.2:n.-926C>T, XR_430455.2:n.-926T>C, XR_952745.1:n.1663-1A>G, XR_952745.1:n.1663-1G>A, rs1800716, rs28371711, rs60082401, rs606231227
C > T
SNP
No VIP available No Clinical Annotations available VA
rs4253778 NC_000022.10:g.46630634G>C, NC_000022.11:g.46234737G>C, NG_012204.1:g.89136G>C, NM_001001928.2:c.1160-396G>C, NM_005036.4:c.1160-396G>C, XM_005261653.1:c.1160-396G>C, XM_005261654.1:c.1160-396G>C, XM_005261655.1:c.1160-396G>C, XM_005261655.2:c.1160-396G>C, XM_005261656.1:c.1160-396G>C, XM_005261656.2:c.1160-396G>C, XM_005261657.1:c.1160-396G>C, XM_005261658.1:c.1160-396G>C, XM_006724269.2:c.1160-396G>C, XM_006724270.2:c.1160-396G>C, XM_011530239.1:c.1160-396G>C, XM_011530240.1:c.1160-396G>C, XM_011530241.1:c.1160-396G>C, XM_011530242.1:c.1160-396G>C, XM_011530243.1:c.1160-396G>C, XM_011530244.1:c.758-396G>C, XM_011530245.1:c.758-396G>C, XR_244379.1:n.1184-396G>C, XR_937869.1:n.1276-396G>C, XR_937870.1:n.1271-396G>C, rs17248629, rs57323063, rs61046783
G > C
SNP
No VIP available No Clinical Annotations available VA
rs4994 NC_000008.10:g.37823798A>G, NC_000008.11:g.37966280A>G, NG_011936.1:g.5387T>C, NM_000025.2:c.190T>C, NP_000016.1:p.Trp64Arg, rs117258787, rs17025
A > G
SNP
W64R
rs5030655 NC_000022.10:g.42525086delA, NC_000022.11:g.42129084delA, NG_008376.3:g.5908delT, NM_000106.5:c.454delT, NM_001025161.2:c.353-140delT, NP_000097.3:p.Trp152Glyfs, NT_187682.1:g.51425delA, NW_004504305.1:g.51411delA, NW_009646208.1:g.14650delA, XM_005278353.1:c.363-141delT, XM_005278354.1:c.155delT, XM_005278354.3:c.155delT, XM_011529966.1:c.454delT, XM_011529967.1:c.454delT, XM_011529968.1:c.454delT, XM_011529969.1:c.311delT, XM_011529970.1:c.353-140delT, XM_011529971.1:c.311delT, XM_011529972.1:c.454delT, XM_011547541.1:c.155delT, XM_011547750.1:c.311delT, XM_011547751.1:c.238delT, XM_011547756.1:c.-951delA, XM_011548819.1:c.155delT, XP_005278411.1:p.Val52Glyfs, XP_011528268.1:p.Trp152Glyfs, XP_011528269.1:p.Trp152Glyfs, XP_011528270.1:p.Trp152Glyfs, XP_011528271.1:p.Val104Glyfs, XP_011528273.1:p.Val104Glyfs, XP_011528274.1:p.Trp152Glyfs, XP_011545843.1:p.Val52Glyfs, XP_011546052.1:p.Val104Glyfs, XP_011546053.1:p.Trp80Glyfs, XP_011547121.1:p.Val52Glyfs, XR_430455.2:n.-787delA, XR_952745.1:n.1611delT, rs11568727, rs28371709
A > -
A > A
indel
W152G
VIP No Clinical Annotations available No Variant Annotations available
rs5030656 NC_000022.10:g.42524176_42524178delCTT, NC_000022.11:g.42128174_42128176delCTT, NG_008376.3:g.6816_6818delAAG, NM_000106.5:c.841_843delAAG, NM_001025161.2:c.688_690delAAG, NP_000097.3:p.Lys281del, NP_001020332.2:p.Lys230del, NT_187682.1:g.50515_50517delCTT, NW_004504305.1:g.50501_50503delCTT, NW_009646208.1:g.13740_13742delCTT, XM_005278353.1:c.697_699delAAG, XM_005278354.1:c.541_543delAAG, XM_005278354.3:c.541_543delAAG, XM_011529966.1:c.841_843delAAG, XM_011529967.1:c.841_843delAAG, XM_011529968.1:c.841_843delAAG, XM_011529969.1:c.697_699delAAG, XM_011529970.1:c.688_690delAAG, XM_011529971.1:c.697_699delAAG, XM_011529972.1:c.841_843delAAG, XM_011547541.1:c.541_543delAAG, XM_011547750.1:c.697_699delAAG, XM_011547751.1:c.625_627delAAG, XM_011547756.1:c.-1861_-1859del, XM_011548819.1:c.541_543delAAG, XP_005278410.1:p.Lys233del, XP_005278411.1:p.Lys181del, XP_011528268.1:p.Lys281del, XP_011528269.1:p.Lys281del, XP_011528270.1:p.Lys281del, XP_011528271.1:p.Lys233del, XP_011528272.1:p.Lys230del, XP_011528273.1:p.Lys233del, XP_011528274.1:p.Lys281del, XP_011545843.1:p.Lys181del, XP_011546052.1:p.Lys233del, XP_011546053.1:p.Lys209del, XP_011547121.1:p.Lys181del, XR_430455.2:n.-1697_-1695del, XR_952745.1:n.1998_2000delAAG, rs587777919
CTT > -
CTT > CTT
indel
VIP No Clinical Annotations available No Variant Annotations available
rs59421388 NC_000022.10:g.42523610C>T, NC_000022.11:g.42127608C>T, NG_008376.3:g.7384G>A, NM_000106.5:c.1012G>A, NM_001025161.2:c.859G>A, NP_000097.3:p.Val338Met, NP_001020332.2:p.Val287Met, NT_187682.1:g.49949C>T, NW_004504305.1:g.49935C>T, NW_009646208.1:g.13174C>T, XM_005278353.1:c.868G>A, XM_005278354.1:c.712G>A, XM_005278354.3:c.712G>A, XM_011529966.1:c.1012G>A, XM_011529967.1:c.1012G>A, XM_011529968.1:c.1012G>A, XM_011529969.1:c.868G>A, XM_011529970.1:c.859G>A, XM_011529971.1:c.868G>A, XM_011529972.1:c.870G>A, XM_011547541.1:c.*118G>A, XM_011547750.1:c.868G>A, XM_011547751.1:c.796G>A, XM_011548819.1:c.*118G>A, XP_005278410.1:p.Val290Met, XP_005278411.1:p.Val238Met, XP_011528268.1:p.Val338Met, XP_011528269.1:p.Val338Met, XP_011528270.1:p.Val338Met, XP_011528271.1:p.Val290Met, XP_011528272.1:p.Val287Met, XP_011528273.1:p.Val290Met, XP_011528274.1:p.Thr290=, XP_011546052.1:p.Val290Met, XP_011546053.1:p.Val266Met, XR_952745.1:n.2027G>A
C > T
SNP
V338M
VIP No Clinical Annotations available No Variant Annotations available
rs61736512 NC_000022.10:g.42525134C>T, NC_000022.11:g.42129132C>T, NG_008376.3:g.5860G>A, NM_000106.5:c.406G>A, NM_001025161.2:c.353-188G>A, NP_000097.3:p.Val136Met, NT_187682.1:g.51473C>T, NW_004504305.1:g.51459C>T, NW_009646208.1:g.14698C>T, XM_005278353.1:c.363-189G>A, XM_005278354.1:c.107G>A, XM_005278354.3:c.107G>A, XM_011529966.1:c.406G>A, XM_011529967.1:c.406G>A, XM_011529968.1:c.406G>A, XM_011529969.1:c.263G>A, XM_011529970.1:c.353-188G>A, XM_011529971.1:c.263G>A, XM_011529972.1:c.406G>A, XM_011547541.1:c.107G>A, XM_011547750.1:c.263G>A, XM_011547751.1:c.190G>A, XM_011547756.1:c.-903C>T, XM_011548819.1:c.107G>A, XP_005278411.1:p.Arg36His, XP_011528268.1:p.Val136Met, XP_011528269.1:p.Val136Met, XP_011528270.1:p.Val136Met, XP_011528271.1:p.Arg88His, XP_011528273.1:p.Arg88His, XP_011528274.1:p.Val136Met, XP_011545843.1:p.Arg36His, XP_011546052.1:p.Arg88His, XP_011546053.1:p.Val64Ile, XP_011547121.1:p.Arg36His, XR_430455.2:n.-739C>T, XR_952745.1:n.1563G>A
C > T
SNP
V136M
No VIP available No Clinical Annotations available VA
rs61767072 NC_000004.11:g.3769297_3769308delGGGGCGGGGCCG, NC_000004.12:g.3767570_3767581delGGGGCGGGGCCG, NG_012640.1:g.6002_6013delGGGGCGGGGCCG, NM_000683.3:c.964_975delGGGGCGGGGCCG, NP_000674.2:p.Gly324_Ala327del
GGGGCGGGGCCG > -
indel
No VIP available No Clinical Annotations available VA
rs8175347
(TA)6 > (TA)5
(TA)6 > (TA)7
(TA)6 > (TA)8
microsatellite
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 147

Overview

Generic Names
  • Metoprolol Tartrate
  • Metoprolol succinate
Trade Names
  • Beloc
  • Betaloc
  • Lopresor
  • Lopresoretic
  • Lopressor
  • Lopressor HCT
  • Metroprolol
  • Prelis
  • Selo-Zok
  • Seloken
  • Selopral
  • Toprol
  • Toprol XL
  • Toprol-XL
Brand Mixture Names

PharmGKB Accession Id

PA450480

Type(s):

Drug

Description

Metoprolol is a cardioselective beta1-adrenergic blocking agent used for acute myocardial infarction (MI), heart failure, angina pectoris and mild to moderate hypertension. It may also be used for supraventricular and tachyarrhythmias and prophylaxis for migraine headaches. Metoprolol is structurally similar to bisoprolol, acebutolol and atenolol in that it has two substituents in the para position of the benzene ring. The beta1-selectivity of these agents is thought to be due in part to the large substituents in the para position. At low doses, metoprolol selectively blocks cardiac beta-1-adrenergic receptors with little activity against beta2-adrenergic receptors of the lungs and vascular smooth muscle. Receptor selectivity decreases with higher doses. Unlike propranolol and pindolol, metoprolol does not exhibit membrane-stabilizing or intrinsic sympathomimetic activity. Membrane-stabilizing effects are only observed at doses much higher than those needed for beta-adrenergic blocking activity. Metoprolol possesses a single chiral centre and is administered as a racemic mixture.

Source: Drug Bank

Indication

For the management of acute myocardial infarction, angina pectoris, heart failure and mild to moderate hypertension. May be used to treat supraventricular and tachyarrhythmias and as prophylaxis for migraine headaches.

Source: Drug Bank

Other Vocabularies

Information pulled from DrugBank has not been reviewed by PharmGKB.

Pharmacology, Interactions, and Contraindications

Mechanism of Action

Metoprolol competes with adrenergic neurotransmitters such as catecholamines for binding at beta(1)-adrenergic receptors in the heart. Beta(1)-receptor blockade results in a decrease in heart rate, cardiac output, and blood pressure.

Source: Drug Bank

Pharmacology

Metoprolol, a competitive, beta1-selective (cardioselective) adrenergic antagonist, is similar to atenolol in its moderate lipid solubility, lack of intrinsic sympathomimetic activity (ISA), and weak membrane stabilizing activity (MSA).

Source: Drug Bank

Food Interaction

Avoid alcohol.|Avoid natural licorice.|Take with food.

Source: Drug Bank

Absorption, Distribution, Metabolism, Elimination & Toxicity

Biotransformation

Primarily hepatic

Source: Drug Bank

Protein Binding

12%

Source: Drug Bank

Absorption

Rapid and complete, 50%

Source: Drug Bank

Half-Life

3-7 hours

Source: Drug Bank

Toxicity

LD 50=5500 mg/kg (orally in rats), toxic effects include bradycardia, hypotension, bronchospasm, and cardiac failure. LD 50=2090 mg/kg (orally in mice)

Source: Drug Bank

Route of Elimination

Less than 5% of an oral dose of metoprolol is recovered unchanged in the urine; the rest is excreted by the kidneys as metabolites that appear to have no beta-blocking activity.

Source: Drug Bank

Chemical Properties

Chemical Formula

C15H25NO3

Source: Drug Bank

Isomeric SMILES

CC(C)NCC(COc1ccc(cc1)CCOC)O

Source: OpenEye

Canonical SMILES

COCCC1=CC=C(OCC(O)CNC(C)C)C=C1

Source: Drug Bank

Average Molecular Weight

267.3639

Source: Drug Bank

Monoisotopic Molecular Weight

267.183443671

Source: Drug Bank

SMILES

COCCC1=CC=C(OCC(O)CNC(C)C)C=C1

Source: Drug Bank

InChI String

InChI=1S/C15H25NO3/c1-12(2)16-10-14(17)11-19-15-6-4-13(5-7-15)8-9-18-3/h4-7,12,14,16-17H,8-11H2,1-3H3

Source: Drug Bank

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

  1. Beta-agonist/Beta-blocker Pathway, Pharmacodynamics
    Simplified pharmacodynamic pathway of drug action on beta 2 adrenergic receptor in a stylized airway cell.

External Pathways

Links to non-PharmGKB pathways.

PharmGKB contains no links to external pathways for this drug. To report a pathway, click here.

Genes that are associated with this drug in PharmGKB's database based on (1) variant annotations, (2) literature review, (3) pathways or (4) information automatically retrieved from DrugBank, depending on the "evidence" and "source" listed below.

Curated Information ?

Drug Targets

Gene Description
ADRB1 (source: Drug Bank)
ADRB2 (source: Drug Bank)

Drug Interactions

Interaction Description
acetohexamide - metoprolol The beta-blocker, metoprolol, may decrease symptoms of hypoglycemia. (source: Drug Bank)
chlorpropamide - metoprolol The beta-blocker decreases the symptoms of hypoglycemia (source: Drug Bank)
chlorpropamide - metoprolol The beta-blocker, metoprolol, may decrease symptoms of hypoglycemia. (source: Drug Bank)
cimetidine - metoprolol Increases the effect of the beta-blocker (source: Drug Bank)
cimetidine - metoprolol Cimetidine may increase the serum concentration of metoprolol by decreasing its metabolism. (source: Drug Bank)
citalopram - metoprolol The SSRI increases the effect of the beta-blocker (source: Drug Bank)
citalopram - metoprolol The SSRI, citalopram, may increase the bradycardic effect of the beta-blocker, metoprolol. (source: Drug Bank)
clonidine - metoprolol Increased hypertension when clonidine stopped (source: Drug Bank)
clonidine - metoprolol Increased hypertension when clonidine stopped (source: Drug Bank)
dihydroergotamine - metoprolol Ischemia with risk of gangrene (source: Drug Bank)
dihydroergotamine - metoprolol Ischemia with risk of gangrene (source: Drug Bank)
diltiazem - metoprolol Increased risk of bradycardia (source: Drug Bank)
diltiazem - metoprolol Increased risk of bradycardia (source: Drug Bank)
disopyramide - metoprolol The beta-blocker increases toxicity of disopyramide (source: Drug Bank)
disopyramide - metoprolol The beta-blocker, metoprolol, may increase the toxicity of disopyramide. (source: Drug Bank)
epinephrine - metoprolol Hypertension, then bradycardia (source: Drug Bank)
epinephrine - metoprolol Hypertension, then bradycardia (source: Drug Bank)
ergotamine - metoprolol Ischemia with risk of gangrene (source: Drug Bank)
ergotamine - metoprolol Ischemia with risk of gangrene (source: Drug Bank)
escitalopram - metoprolol The SSRI increases the effect of the beta-blocker (source: Drug Bank)
escitalopram - metoprolol The SSRI, escitalopram, may increase the bradycardic effect of the beta-blocker, metoprolol. (source: Drug Bank)
fenoterol - metoprolol Antagonism (source: Drug Bank)
fenoterol - metoprolol Antagonism (source: Drug Bank)
fluoxetine - metoprolol The SSRI increases the effect of the beta-blocker (source: Drug Bank)
fluoxetine - metoprolol The SSRI, fluoxetine, may increase the bradycardic effect of the beta-blocker, metoprolol. (source: Drug Bank)
formoterol - metoprolol Antagonism (source: Drug Bank)
formoterol - metoprolol Antagonism (source: Drug Bank)
glibenclamide - metoprolol The beta-blocker decreases the symptoms of hypoglycemia (source: Drug Bank)
glibenclamide - metoprolol The beta-blocker, metoprolol, may decrease symptoms of hypoglycemia. (source: Drug Bank)
gliclazide - metoprolol The beta-blocker decreases the symptoms of hypoglycemia (source: Drug Bank)
gliclazide - metoprolol The beta-blocker, metoprolol, may decrease symptoms of hypoglycemia. (source: Drug Bank)
ibuprofen - metoprolol Risk of inhibition of renal prostaglandins (source: Drug Bank)
ibuprofen - metoprolol Risk of inhibition of renal prostaglandins (source: Drug Bank)
indomethacin - metoprolol Risk of inhibition of renal prostaglandins (source: Drug Bank)
indomethacin - metoprolol Risk of inhibition of renal prostaglandins (source: Drug Bank)
insulin-glargine - metoprolol The beta-blocker, metoprolol, may decrease symptoms of hypoglycemia. (source: Drug Bank)
insulin-glargine - metoprolol The beta-blocker, metoprolol, may decrease symptoms of hypoglycemia. (source: Drug Bank)
methysergide - metoprolol Ischemia with risk of gangrene (source: Drug Bank)
methysergide - metoprolol Ischemia with risk of gangrene (source: Drug Bank)
metoprolol - acetohexamide The beta-blocker decreases the symptoms of hypoglycemia (source: Drug Bank)
metoprolol - acetohexamide The beta-blocker, metoprolol, may decrease symptoms of hypoglycemia. (source: Drug Bank)
metoprolol - amobarbital The barbiturate decreases the effect of metabolized beta-blocker (source: Drug Bank)
metoprolol - amobarbital The barbiturate decreases the effect of metabolized beta-blocker (source: Drug Bank)
metoprolol - aprobarbital The barbiturate decreases the effect of metabolized beta-blocker (source: Drug Bank)
metoprolol - aprobarbital The barbiturate decreases the effect of metabolized beta-blocker (source: Drug Bank)
metoprolol - butabarbital The barbiturate decreases the effect of metabolized beta-blocker (source: Drug Bank)
metoprolol - butabarbital The barbiturate decreases the effect of metabolized beta-blocker (source: Drug Bank)
metoprolol - butalbital The barbiturate decreases the effect of metabolized beta-blocker (source: Drug Bank)
metoprolol - butalbital The barbiturate decreases the effect of metabolized beta-blocker (source: Drug Bank)
metoprolol - butethal The barbiturate decreases the effect of metabolized beta-blocker (source: Drug Bank)
metoprolol - butethal The barbiturate decreases the effect of metabolized beta-blocker (source: Drug Bank)
metoprolol - chlorpropamide The beta-blocker decreases the symptoms of hypoglycemia (source: Drug Bank)
metoprolol - chlorpropamide The beta-blocker, metoprolol, may decrease symptoms of hypoglycemia. (source: Drug Bank)
metoprolol - cimetidine Cimetidine increases the effect of the beta-blocker (source: Drug Bank)
metoprolol - cimetidine Cimetidine may increase the serum concentration of metoprolol by decreasing its metabolism. (source: Drug Bank)
metoprolol - citalopram The SSRI increases the effect of the beta-blocker (source: Drug Bank)
metoprolol - citalopram The SSRI, citalopram, may increase the bradycardic effect of the beta-blocker, metoprolol. (source: Drug Bank)
metoprolol - clonidine Increased hypertension when clonidine stopped (source: Drug Bank)
metoprolol - clonidine Increased hypertension when clonidine stopped (source: Drug Bank)
metoprolol - dihydroergotamine Ischemia with risk of gangrene (source: Drug Bank)
metoprolol - dihydroergotamine Ischemia with risk of gangrene (source: Drug Bank)
metoprolol - dihydroergotoxine Ischemia with risk of gangrene (source: Drug Bank)
metoprolol - dihydroergotoxine Ischemia with risk of gangrene (source: Drug Bank)
metoprolol - diltiazem Increased risk of bradycardia (source: Drug Bank)
metoprolol - diltiazem Increased risk of bradycardia (source: Drug Bank)
metoprolol - disopyramide The beta-blocker increases toxicity of disopyramide (source: Drug Bank)
metoprolol - disopyramide The beta-blocker, metoprolol, may increase toxicity of disopyramide. (source: Drug Bank)
metoprolol - epinephrine Hypertension, then bradycardia (source: Drug Bank)
metoprolol - epinephrine Hypertension, then bradycardia (source: Drug Bank)
metoprolol - ergonovine Ischemia with risk of gangrene (source: Drug Bank)
metoprolol - ergonovine Ischemia with risk of gangrene (source: Drug Bank)
metoprolol - ergotamine Ischemia with risk of gangrene (source: Drug Bank)
metoprolol - ergotamine Ischemia with risk of gangrene (source: Drug Bank)
metoprolol - escitalopram The SSRI increases the effect of the beta-blocker (source: Drug Bank)
metoprolol - escitalopram The SSRI increases the effect of the beta-blocker (source: Drug Bank)
metoprolol - fenoterol Antagonism (source: Drug Bank)
metoprolol - fenoterol Antagonism (source: Drug Bank)
metoprolol - fluoxetine The SSRI increases the effect of the beta-blocker (source: Drug Bank)
metoprolol - fluoxetine The SSRI increases the effect of the beta-blocker (source: Drug Bank)
metoprolol - formoterol Antagonism (source: Drug Bank)
metoprolol - formoterol Antagonism (source: Drug Bank)
metoprolol - glibenclamide The beta-blocker decreases the symptoms of hypoglycemia (source: Drug Bank)
metoprolol - glibenclamide The beta-blocker, metoprolol, may decrease symptoms of hypoglycemia. (source: Drug Bank)
metoprolol - gliclazide The beta-blocker decreases the symptoms of hypoglycemia (source: Drug Bank)
metoprolol - gliclazide The beta-blocker, metoprolol, may decrease symptoms of hypoglycemia. (source: Drug Bank)
metoprolol - glipizide The beta-blocker decreases the symptoms of hypoglycemia (source: Drug Bank)
metoprolol - glipizide The beta-blocker, metoprolol, may decrease symptoms of hypoglycemia. (source: Drug Bank)
metoprolol - glisoxepide The beta-blocker decreases the symptoms of hypoglycemia (source: Drug Bank)
metoprolol - glisoxepide The beta-blocker, metoprolol, may decrease symptoms of hypoglycemia. (source: Drug Bank)
metoprolol - glycodiazine The beta-blocker decreases the symptoms of hypoglycemia (source: Drug Bank)
metoprolol - glycodiazine The beta-blocker, metoprolol, may decrease symptoms of hypoglycemia. (source: Drug Bank)
metoprolol - heptabarbital The barbiturate decreases the effect of metabolized beta-blocker (source: Drug Bank)
metoprolol - heptabarbital The barbiturate decreases the effect of metabolized beta-blocker (source: Drug Bank)
metoprolol - hexobarbital The barbiturate decreases the effect of metabolized beta-blocker (source: Drug Bank)
metoprolol - hexobarbital The barbiturate decreases the effect of metabolized beta-blocker (source: Drug Bank)
metoprolol - hydralazine Increased effect of both drugs (source: Drug Bank)
metoprolol - hydralazine Increased effect of both drugs (source: Drug Bank)
metoprolol - ibuprofen Risk of inhibition of renal prostaglandins (source: Drug Bank)
metoprolol - ibuprofen Risk of inhibition of renal prostaglandins (source: Drug Bank)
metoprolol - indomethacin Risk of inhibition of renal prostaglandins (source: Drug Bank)
metoprolol - indomethacin Risk of inhibition of renal prostaglandins (source: Drug Bank)
metoprolol - isoproterenol Antagonism (source: Drug Bank)
metoprolol - isoproterenol Antagonism (source: Drug Bank)
metoprolol - lidocaine The beta-blocker increases the effect and toxicity of lidocaine (source: Drug Bank)
metoprolol - lidocaine The beta-blocker, metoprolol, may increase the effect and toxicity of lidocaine (source: Drug Bank)
metoprolol - methohexital The barbiturate decreases the effect of metabolized beta-blocker (source: Drug Bank)
metoprolol - methohexital The barbiturate decreases the effect of metabolized beta-blocker (source: Drug Bank)
metoprolol - methylphenobarbital The barbiturate decreases the effect of metabolized beta-blocker (source: Drug Bank)
metoprolol - methylphenobarbital The barbiturate decreases the effect of metabolized beta-blocker (source: Drug Bank)
metoprolol - methysergide Ischemia with risk of gangrene (source: Drug Bank)
metoprolol - methysergide Ischemia with risk of gangrene (source: Drug Bank)
metoprolol - orciprenaline Antagonism (source: Drug Bank)
metoprolol - orciprenaline Antagonism (source: Drug Bank)
metoprolol - paroxetine The SSRI increases the effect of the beta-blocker (source: Drug Bank)
metoprolol - paroxetine The SSRI increases the effect of the beta-blocker (source: Drug Bank)
metoprolol - pentobarbital The barbiturate decreases the effect of metabolized beta-blocker (source: Drug Bank)
metoprolol - pentobarbital The barbiturate decreases the effect of metabolized beta-blocker (source: Drug Bank)
metoprolol - phenobarbital The barbiturate decreases the effect of metabolized beta-blocker (source: Drug Bank)
metoprolol - phenobarbital The barbiturate decreases the effect of metabolized beta-blocker (source: Drug Bank)
metoprolol - pirbuterol Antagonism (source: Drug Bank)
metoprolol - pirbuterol Antagonism (source: Drug Bank)
metoprolol - piroxicam Risk of inhibition of renal prostaglandins (source: Drug Bank)
metoprolol - piroxicam Risk of inhibition of renal prostaglandins (source: Drug Bank)
metoprolol - prazosin Risk of hypotension at the beginning of therapy (source: Drug Bank)
metoprolol - prazosin Risk of hypotension at the beginning of therapy (source: Drug Bank)
metoprolol - primidone The barbiturate decreases the effect of metabolized beta-blocker (source: Drug Bank)
metoprolol - primidone The barbiturate decreases the effect of metabolized beta-blocker (source: Drug Bank)
metoprolol - procaterol Antagonism (source: Drug Bank)
metoprolol - procaterol Antagonism (source: Drug Bank)
metoprolol - propafenone Propafenone increases the effect of beta-blocker (source: Drug Bank)
metoprolol - propafenone Propafenone may increase the effect of beta-blocker, metoprolol. (source: Drug Bank)
metoprolol - quinidine The barbiturate decreases the effect of metabolized beta-blocker (source: Drug Bank)
metoprolol - quinidine The barbiturate decreases the effect of metabolized beta-blocker (source: Drug Bank)
metoprolol - repaglinide The beta-blocker decreases the symptoms of hypoglycemia (source: Drug Bank)
metoprolol - repaglinide The beta-blocker, metoprolol, may decrease symptoms of hypoglycemia. (source: Drug Bank)
metoprolol - rifampin Rifampin decreases the effect of the metabolized beta-blocker (source: Drug Bank)
metoprolol - rifampin Rifampin may decrease the serum concentration of metoprolol by increasing its metabolism. (source: Drug Bank)
metoprolol - salbutamol Antagonism (source: Drug Bank)
metoprolol - salbutamol Antagonism (source: Drug Bank)
metoprolol - salmeterol Antagonism (source: Drug Bank)
metoprolol - salmeterol Antagonism (source: Drug Bank)
metoprolol - secobarbital The barbiturate decreases the effect of metabolized beta-blocker (source: Drug Bank)
metoprolol - secobarbital The barbiturate decreases the effect of metabolized beta-blocker (source: Drug Bank)
metoprolol - sertraline The SSRI increases the effect of the beta-blocker (source: Drug Bank)
metoprolol - sertraline The SSRI increases the effect of the beta-blocker (source: Drug Bank)
metoprolol - talbutal The barbiturate decreases the effect of metabolized beta-blocker (source: Drug Bank)
metoprolol - talbutal The barbiturate decreases the effect of metabolized beta-blocker (source: Drug Bank)
metoprolol - telithromycin Telithromycin may possibly increase metoprolol effect (source: Drug Bank)
metoprolol - telithromycin Telithromycin may possibly increase metoprolol effect (source: Drug Bank)
metoprolol - terbutaline Antagonism (source: Drug Bank)
metoprolol - terbutaline Antagonism (source: Drug Bank)
metoprolol - tolazamide The beta-blocker decreases the symptoms of hypoglycemia (source: Drug Bank)
metoprolol - tolazamide The beta-blocker, metoprolol, may decrease symptoms of hypoglycemia. (source: Drug Bank)
metoprolol - tolbutamide The beta-blocker decreases the symptoms of hypoglycemia (source: Drug Bank)
metoprolol - tolbutamide The beta-blocker, metoprolol, may decrease symptoms of hypoglycemia. (source: Drug Bank)
metoprolol - verapamil Increased effect of both drugs (source: Drug Bank)
metoprolol - verapamil Increased effect of both drugs (source: Drug Bank)
orciprenaline - metoprolol Antagonism (source: Drug Bank)
orciprenaline - metoprolol Antagonism (source: Drug Bank)
phenobarbital - metoprolol The barbiturate decreases the effect of the metabolized beta-blocker (source: Drug Bank)
phenobarbital - metoprolol The barbiturate decreases the effect of the metabolized beta-blocker (source: Drug Bank)
pipobroman - metoprolol Antagonism (source: Drug Bank)
piroxicam - metoprolol Risk of inhibition of renal prostaglandins (source: Drug Bank)
piroxicam - metoprolol Risk of inhibition of renal prostaglandins (source: Drug Bank)
prazosin - metoprolol Risk of hypotension at the beginning of therapy (source: Drug Bank)
prazosin - metoprolol Risk of hypotension at the beginning of therapy (source: Drug Bank)
primidone - metoprolol The barbiturate decreases the effect of metabolized beta-blocker (source: Drug Bank)
primidone - metoprolol The barbiturate decreases the effect of metabolized beta-blocker (source: Drug Bank)
propafenone - metoprolol Propafenone increases the effect of the beta-blocker (source: Drug Bank)
propafenone - metoprolol Propafenone increases the effect of the beta-blocker (source: Drug Bank)
repaglinide - metoprolol The beta-blocker decreases the symptoms of hypoglycemia (source: Drug Bank)
repaglinide - metoprolol The beta-blocker, metoprolol, may decrease symptoms of hypoglycemia. (source: Drug Bank)
rifampin - metoprolol Rifampin decreases the effect of the metabolized beta-blocker (source: Drug Bank)
rifampin - metoprolol Rifampin may decrease the serum concentration of metoprolol by increasing its metabolism. (source: Drug Bank)
telithromycin - metoprolol Telithromycin may possibly increase metoprolol effect (source: Drug Bank)
terazosin - metoprolol Increased risk of hypotension. Initiate concomitant therapy cautiously. (source: Drug Bank)
terbutaline - metoprolol Antagonism (source: Drug Bank)
terbutaline - metoprolol Antagonism (source: Drug Bank)
trazodone - metoprolol The 2D6 inhibitor, Trazodone, may increase the efficacy of Metoprolol by decreasing Metoprolol metabolism and clearance. Monitor for changes in Metoprolol efficacy if Trazodone is initiated, discontinued or dose changed. (source: Drug Bank)
trazodone - metoprolol The 2D6 inhibitor, Trazodone, may increase the efficacy of Metoprolol by decreasing Metoprolol metabolism and clearance. Monitor for changes in Metoprolol efficacy if Trazodone is initiated, discontinued or dose changed. (source: Drug Bank)
treprostinil - metoprolol Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. (source: Drug Bank)

Curated Information ?

EvidenceDisease
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Acute coronary syndrome
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Alzheimer Disease
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Arrhythmias, Cardiac
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Arthritis, Rheumatoid
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Atrial Fibrillation
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Attention Deficit Disorder with Hyperactivity
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Bipolar Disorder
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Bradycardia
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Breast Neoplasms
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Carcinoma, Non-Small-Cell Lung
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Carcinoma, Renal Cell
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cardiomyopathy, Dilated
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cardiomyopathy, Hypertrophic
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Carotid Stenosis
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
codeine dependence
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Colorectal Neoplasms
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Coronary Artery Disease
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Crohn Disease
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cystic Fibrosis
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Death
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Depression
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Depressive Disorder, Major
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Drug Toxicity
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Epilepsy
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Esophagitis
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Essential hypertension
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Gastrointestinal Stromal Tumors
No Dosing Guideline available DL CA VA No VIP available No VIP available
Heart Failure
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
HIV Infections
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Hypercholesterolemia
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Hypereosinophilic Syndrome
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Hyperlipoproteinemia Type II
No Dosing Guideline available DL CA VA No VIP available No VIP available
Hypertension
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
hypertensive nephrosclerosis
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Hypertriglyceridemia
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Hypotension
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Inflammatory Bowel Diseases
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Kidney Diseases
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Kidney Transplantation
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Leukemia
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Leukemia, Lymphocytic, Chronic, B-Cell
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Leukemia, Myeloid, Acute
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Leukemia, Nonlymphocytic, Acute
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Leukemia, Promyelocytic, Acute
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Long QT Syndrome
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Lymphoma
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Malaria
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Muscular Diseases
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Mycoses
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Myelodysplastic Syndromes
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Myocardial Infarction
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Neoplasm Metastasis
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Nephrosclerosis
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Ocular Hypertension
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pain
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Peripheral Vascular Diseases
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Precursor Cell Lymphoblastic Leukemia-Lymphoma
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Pregnancy
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pregnancy Complications
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pulmonary Disease, Chronic Obstructive
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pulmonary Fibrosis
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Schizophrenia
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Sjogren's Syndrome
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Stroke
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Thromboembolism
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Thrombosis
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Toxic liver disease
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Tuberculosis, Pulmonary
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Tumor Lysis Syndrome
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Urinary Incontinence

Relationships from National Drug File - Reference Terminology (NDF-RT)

May Treat
Contraindicated With

Publications related to metoprolol: 75

No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacogenomic Genome-Wide Meta-Analysis of Blood Pressure Response to beta-Blockers in Hypertensive African Americans. Hypertension. 2016. Gong Yan, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacokinetics of metoprolol during pregnancy and lactation. Journal of clinical pharmacology. 2015. Ryu Rachel J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Evidence for Clinical Implementation of Pharmacogenomics in Cardiac Drugs. Mayo Clinic proceedings. 2015. Kaufman Amy L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Drug disposition and modelling before and after gastric bypass: immediate and controlled-release metoprolol formulations. British journal of clinical pharmacology. 2015. Gesquiere Ina, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomics and cardiology: improving treatment with existing drugs. Pharmacogenomics. 2015. Sorrentino Matthew J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Adoption of a clinical pharmacogenomics implementation program during outpatient care-initial results of the University of Chicago "1,200 Patients Project". American journal of medical genetics. Part C, Seminars in medical genetics. 2014. O'Donnell Peter H, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
An Investigation of CYP2D6 Genotype and Response to Metoprolol CR/XL During Dose Titration in Patients With Heart Failure: A MERIT-HF Substudy. Clinical pharmacology and therapeutics. 2014. Batty J A, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Impact of CYP2D6 polymorphisms on clinical efficacy & tolerability of metoprolol tartrate. Clinical pharmacology and therapeutics. 2014. Hamadeh Issam S, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Meta-analysis of CYP2D6 Metabolizer Phenotype and Metoprolol Pharmacokinetics. Clinical pharmacology and therapeutics. 2013. Blake C M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Challenges in pharmacogenetics. European journal of clinical pharmacology. 2013. Cascorbi Ingolf, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics and other reasons why drugs can fail in pregnancy: higher dose or different drug?. Obstetrics and gynecology. 2012. Haas David M, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Impact of the beta1-Adrenoceptor Arg389Gly Polymorphism on Heart-Rate Responses to Bisoprolol and Carvedilol in Heart-Failure Patients. Clinical pharmacology and therapeutics. 2012. Rau T, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomics of the heptahelical receptor regulators G-protein-coupled receptor kinases and arrestins: the known and the unknown. Pharmacogenomics. 2012. Lymperopoulos Anastasios, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
A Common beta1-Adrenergic Receptor Polymorphism Predicts Favorable Response to Rate-Control Therapy in Atrial Fibrillation. Journal of the American College of Cardiology. 2012. Parvez Babar, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Combinatorial pharmacogenetic interactions of bucindolol and beta1, alpha2C adrenergic receptor polymorphisms. PloS one. 2012. O'Connor Christopher M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The Arg389Gly beta1-adrenoceptor gene polymorphism influences the acute effects of beta-adrenoceptor blockade on contractility in the human heart. Clinical research in cardiology : official journal of the German Cardiac Society. 2011. Huntgeburth Michael, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomics: the genetics of variable drug responses. Circulation. 2011. Roden Dan M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics: From Bench to Byte- An Update of Guidelines. Clinical pharmacology and therapeutics. 2011. Swen J J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Copy number variants in pharmacogenetic genes. Trends in molecular medicine. 2011. He Yijing, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Systematic review of pharmacoeconomic studies of pharmacogenomic tests. Pharmacogenomics. 2010. Beaulieu Mathieu, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Novel KCNA5 mutation implicates tyrosine kinase signaling in human atrial fibrillation. Heart rhythm : the official journal of the Heart Rhythm Society. 2010. Yang Tao, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
beta-blocker therapy and heart rate control during exercise testing in the general population: role of a common G-protein beta-3 subunit variant. Pharmacogenomics. 2010. Dörr Marcus, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Relation of ADRB1, CYP2D6, and UGT1A1 polymorphisms with dose of, and response to, carvedilol or metoprolol therapy in patients with chronic heart failure. The American journal of cardiology. 2010. Baudhuin Linnea M, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Common genetic variation of beta1- and beta2-adrenergic receptor and response to four classes of antihypertensive treatment. Pharmacogenetics and genomics. 2010. Suonsyrjä Timo, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Nationwide drug-dispensing data reveal important differences in adherence to drug label recommendations on CYP2D6-dependent drug interactions. British journal of clinical pharmacology. 2010. Mannheimer Buster, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomics of antihypertensive drugs: past, present and future. Pharmacogenomics. 2010. Johnson Julie A. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A gene score of nine LDL and HDL regulating genes is associated with fluvastatin-induced cholesterol changes in women. Journal of lipid research. 2010. Hamrefors Viktor, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Haplotypes of the adrenergic system predict the blood pressure response to beta-blockers in women with essential hypertension. Pharmacogenomics. 2010. Filigheddu Fabiana, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Role of beta-adrenergic receptor gene polymorphisms in the long-term effects of beta-blockade with carvedilol in patients with chronic heart failure. Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy. 2010. Metra Marco, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Cytochrome P450 2D6. Pharmacogenetics and genomics. 2009. Owen Ryan P, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CYP2D6 genotype and its relationship with metoprolol dose, concentrations and effect in patients with systolic heart failure. The pharmacogenomics journal. 2009. Sharp C F, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ADME pharmacogenetics: current practices and future outlook. Expert opinion on drug metabolism & toxicology. 2009. Grossman Iris. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
G-protein-coupled receptor kinase 4 polymorphisms and blood pressure response to metoprolol among African Americans: sex-specificity and interactions. American journal of hypertension. 2009. Bhatnagar Vibha, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Impact of the CYP2D6 genotype on the clinical effects of metoprolol: a prospective longitudinal study. Clinical pharmacology and therapeutics. 2009. Rau T, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic variation in the CYP2D6 gene is associated with a lower heart rate and blood pressure in beta-blocker users. Clinical pharmacology and therapeutics. 2009. Bijl M J, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
beta-adrenergic receptor gene polymorphisms and beta-blocker treatment outcomes in hypertension. Clinical pharmacology and therapeutics. 2008. Pacanowski M A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Analytical and bioanalytical chemistry. 2008. Zanger Ulrich M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Influence of CYP2D6*10 on the pharmacokinetics of metoprolol in healthy Korean volunteers. Journal of clinical pharmacy and therapeutics. 2008. Jin S K, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Beta-1-adrenoceptor genetic variants and ethnicity independently affect response to beta-blockade. Pharmacogenetics and genomics. 2008. Kurnik Daniel, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Interaction between PPARA genotype and beta-blocker treatment influences clinical outcomes following acute coronary syndromes. Pharmacogenomics. 2008. Cresci Sharon, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A GRK5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failure. Nature medicine. 2008. Liggett Stephen B, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Arg389Gly-beta1-adrenergic receptors determine improvement in left ventricular systolic function in nonischemic cardiomyopathy patients with heart failure after chronic treatment with carvedilol. Pharmacogenetics and genomics. 2007. Chen Lu, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Comparison of duloxetine, escitalopram, and sertraline effects on cytochrome P450 2D6 function in healthy volunteers. Journal of clinical psychopharmacology. 2007. Preskorn Sheldon H, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Synergistic polymorphisms of beta1 and alpha2C-adrenergic receptors and the influence on left ventricular ejection fraction response to beta-blocker therapy in heart failure. Pharmacogenetics and genomics. 2007. Lobmeyer Maximilian T, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Beta-2-adrenergic receptor polymorphisms and changes in lipids induced by metoprolol. Pharmacology. 2007. Isaza Carlos A, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
beta1-Adrenergic receptor polymorphisms influence the response to metoprolol monotherapy in patients with essential hypertension. Clinical pharmacology and therapeutics. 2006. Liu Jie, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proceedings of the National Academy of Sciences of the United States of America. 2006. Liggett Stephen B, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Influence of phenotype and pharmacokinetics on beta-blocker drug target pharmacogenetics. The pharmacogenomics journal. 2006. Beitelshees A L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: a prospective clinical study. Clinical pharmacology and therapeutics. 2005. Fux Richard, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Functional analysis of CYP2D6.31 variant: homology modeling suggests possible disruption of redox partner interaction by Arg440His substitution. Proteins. 2005. Allorge Delphine, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Beta1-adrenergic receptor polymorphisms and left ventricular remodeling changes in response to beta-blocker therapy. Pharmacogenetics and genomics. 2005. Terra Steven G, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
beta-Adrenergic receptor polymorphisms and responses during titration of metoprolol controlled release/extended release in heart failure. Clinical pharmacology and therapeutics. 2005. Terra Steven G, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Association between beta-1 and beta-2 adrenergic receptor gene polymorphisms and the response to beta-blockade in patients with stable congestive heart failure. Pharmacogenetics and genomics. 2005. de Groote Pascal, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension. Clinical pharmacology and therapeutics. 2004. Zineh Issam, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
beta-Blockade and increased dyslipidemia in patients bearing Glu27 variant of beta2 adrenergic receptor gene. The pharmacogenomics journal. 2005. Iaccarino G, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Nonlinear mixed effects model analysis of the pharmacokinetics of metoprolol in routinely treated Japanese patients. Biological & pharmaceutical bulletin. 2004. Taguchi Masato, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of antihypertensive drug responses. American journal of pharmacogenomics : genomics-related research in drug development and clinical practice. 2004. Schwartz Gary L, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Gly389Arg polymorphism of beta1-adrenergic receptor is associated with the cardiovascular response to metoprolol. Clinical pharmacology and therapeutics. 2003. Liu Jie, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Beta 1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure. Nature medicine. 2003. Mialet Perez Jeanne, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
An evaluation of the beta-1 adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: a MERIT-HF sub-study. European journal of heart failure : journal of the Working Group on Heart Failure of the European Society of Cardiology. 2003. White Hazel L, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol. Clinical pharmacology and therapeutics. 2003. Johnson Julie A, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
A common beta1-adrenergic receptor polymorphism (Arg389Gly) affects blood pressure response to beta-blockade. Clinical pharmacology and therapeutics. 2003. Sofowora G G, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects. Clinical pharmacology and therapeutics. 2002. Wuttke Henrike, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Effect of the CYP2D6 genotype on metoprolol metabolism persists during long-term treatment. Pharmacogenetics. 2002. Rau Thomas, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The African-specific CYP2D617 allele encodes an enzyme with changed substrate specificity. Clinical pharmacology and therapeutics. 2002. Wennerholm Agneta, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
In-vitro analysis of the contribution of CYP2D6.35 to ultra-rapid metabolism. Pharmacogenetics. 2001. Allorge D, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Characterization of the CYP2D6*29 allele commonly present in a black Tanzanian population causing reduced catalytic activity. Pharmacogenetics. 2001. Wennerholm A, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
A rare G2061 insertion affecting the open reading frame of CYP2D6 and responsible for the poor metabolizer phenotype. Pharmacogenetics. 1999. Marez-Allorge D, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetic determination of the effects of codeine and prediction of drug interactions. The Journal of pharmacology and experimental therapeutics. 1996. Caraco Y, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Steady-state plasma concentrations of imipramine and desipramine in relation to S-mephenytoin 4'-hydroxylation status in Japanese depressive patients. Journal of clinical psychopharmacology. 1996. Koyama E, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Codeine and morphine in extensive and poor metabolizers of sparteine: pharmacokinetics, analgesic effect and side effects. European journal of clinical pharmacology. 1996. Poulsen L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Metabolic disposition of imipramine in oriental subjects: relation to metoprolol alpha-hydroxylation and S-mephenytoin 4'-hydroxylation phenotypes. The Journal of pharmacology and experimental therapeutics. 1994. Koyama E, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Impact of environmental and genetic factors on codeine analgesia. European journal of clinical pharmacology. 1991. Desmeules J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pregnancy-induced increase in metoprolol metabolism. Clinical pharmacology and therapeutics. 1985. Högstedt S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
http://www.sciencenews.org/sn_arc97/9_13_97/fob2.htm. [URL:http://www.sciencenews.org/sn_arc97/9_13_97/fob2.htm]

LinkOuts

Web Resource:
Wikipedia
National Drug Code Directory:
58177-293-04
DrugBank:
DB00264
ChEBI:
6904
KEGG Compound:
C07202
KEGG Drug:
D02358
PubChem Compound:
4171
PubChem Substance:
205122
46506211
IUPHAR Ligand:
553
Drugs Product Database (DPD):
2253518
BindingDB:
25756
ChemSpider:
4027
Therapeutic Targets Database:
DAP000481
FDA Drug Label at DailyMed:
a8374722-d2b5-4eb3-bbcd-6ddc52e763ba

Clinical Trials

These are trials that mention metoprolol and are related to either pharmacogenetics or pharmacogenomics.

No trials loaded.

NURSA Datasets

provided by nursa.org

No NURSA datasets available.

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Sources for PharmGKB drug information: DrugBank, PubChem.